Pasar al contenido principal

Video Library

Learn about bone marrow/stem cell transplant, CAR T-cell therapy, graft-versus-host disease (GVHD), and how to manage late effects of treatment.

Categories
Tags
Transcripción de la Presentación ( 00:00:01) (Julia Pan) Introducción. Bienvenidos al Seminario Web: Prevención y Tratamiento de la Enfermedad Injerto contra Huésped. Este Seminario Web es traído a usted por
There are several safe and effective vaccines for COVID-19. These vaccines are recommended for transplant patients in most circumstances. This presentation reviews guidelines, offers recommendations, and answers questions about the benefits of COVID-19 vaccines for transplant patients.
Myelodysplastic syndrome (MDS) is a blood disorder that can develop into leukemia. There are several treatments for MDS, including stem cell transplantation. This presentation reviews key features of MDS, treatment options and when a transplant is an appropriate remedy.
Acute myeloid leukemia (AML) is a blood cancer that has been historically challenging to treat. It often requires a bone marrow or stem cell transplant that can be curative but brings significant risks and side effects. However, new drugs and clinical trials have expanded treatment options and moderated side effects for many patients.
CAR T cell therapy is a new type of therapy for patients with multiple myeloma. It is currently available for patients who have relapsed after four or more rounds prior therapy. This presentation describes CAR T cell and related therapies as well as new drugs in the pipeline to treat patients with multiple myeloma
Anxiety and depression are common among cancer patients and survivors. Acceptance and commitment therapy is an effective tool for these problems. This presentation discusses the mental health challenges of transplant and GVHD patients and how this therapy can help them.
Sickle cell disease disproportionately affects African Americans. However, stem cell transplants and gene therapy offer promising treatment options. This presentation describes these treatments, their outcomes, and which treatments are appropriate for which patients.
The number of long-term survivors of hematopoietic cell transplants (bone marrow, stem cell, and cord blood) is dramatically increasing. However, up to two thirds of survivors report at least one chronic health condition as a late effect of treatment. This presentation describes these effects and interventions to treat them.
Autologous stem cell transplants use the patient’s own stem cells to rescue him or her from the effects of high-dose chemotherapy. This type of transplant is most often used to treat patients with multiple myeloma, non-Hodgkin lymphoma and Hodgkin lymphoma. This presentation discusses the transplant process, and common early and late complications.
A pediatric bone marrow transplant can cure a child’s disease, but it can also create a number of physical, emotional and financial issues that need to be addressed, even when the child becomes an adult. This presentation discusses common challenges children face after transplant, and strategies to provide them with a good quality of life long-term.
COVID-19 and its variants present ongoing risks to the general population and added risks for cancer patients, people with weak immune systems, and transplant survivors. This presentation reviews the basics about COVID-19, prevention strategies, recent variants, available therapies, and vaccine responses and provides specific advice for cancer patients and survivors.
Graft-versus-Host Disease (GVHD) is a common condition after a bone marrow or stem cell transplant that uses cells from a donor (an allogeneic transplant). The donor cells are called the “graft” and the patient is called the “host”. When the donor’s immune cells (the graft) are transplanted in the patient’s body (the host) they often unleash an immune system attack against the patient’s organs and tissues which can be mild, moderate or severe.